Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
Recruiting
Observational Study
Left Ventricular Remodeling
Plasma Multi-Omics
Acute ST-segment Elevation Myocardial Infarction
Immunomics
Major Adverse Cardiovascular Events
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Beijing Anzhen Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years and ≤80 years.
2. Definite diagnosis of STEMI according to ESC/ACC guidelines:
* Chest pain lasting \>30 minutes, and
* ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other…
Contacts